New 'Living Drug' trial targets tough cancers with engineered immune cells
Disease control
Recruiting now
This is an early-stage study testing the safety of a new type of CAR-T cell therapy called PTC13 in adults with advanced solid tumors that have a marker called CEA. The therapy involves collecting a patient's own immune cells, genetically engineering them in a lab to better targe…
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Apr 01, 2026 20:26 UTC